Octreotide and everolimus have demonstrated efficacy in neuroendocrine tumors. patient; 17 (81%) patients experienced at least some tumor regression as their best response to therapy. In conclusion, pasireotide LAR 60 mg IM monthly in combination with everolimus 10 mg daily…